Construction for Henlius, another major project of the bio-medicine industry, kicked off in the Songjiang G60 Sci-tech Corridor yesterday.
It is designed to be an energy-saving and environment-friendly project, with the world’s latest medicine manufacturing technologies and is set to be top in the nation and third in Asia in terms of production capacity.
The aim of Henlius is to provide global patients with cost-efficient and quality biomedicines. The base will be able to produce 20-30 kinds of products that can satisfy demands for global sales, which include five to 10 biosimilars and 10 to 20 innovation drugs.
These drugs will mainly be used for cancer treatment.
So far the company has filed applications for 23 clinical trials for its 13 products and two therapies and obtained in total 29 trial permits around the world.
Its hit product, rituximab injection, has become the first biosimilar approved for sale in China.
The location in Songjiang will facilitate the company in working with local industrial base as well as quality medical firms in the Yangtze River Delta.
Biomedicine is one of Shanghai’s supporting strategic emerging industries and Songjiang is an important manufacturing base of the industry, gathering about 100 key enterprises.